Treatment options for low-grade serous ovarian carcinoma (LGSOC) are limited due to its complex molecular profile and pathophysiology. However, novel and emerging targeted therapies are improving outcomes for those with LGSOC. In this concise and convenient Booster Quiz, test your knowledge of current LGSOC treatment paradigms and the latest clinical data on safety and efficacy of new and emerging therapies. This unique learning experience provides: instant expert feedback on your answer selections opportunity to see how well you do relative to your peers access to a downloadable summary with key supporting evidence.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/equipping-oncology-teams-latest-evidence-emerging-therapies-low-grade-serous
- Start Date: 2024-07-12 05:00:00
- End Date: 2024-07-12 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Verastem Oncology - Amount: 48333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest